Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 10/20 | 0.58 |
| ▸ | RAF1 | P04049 | 3/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | STK4 | Q13043 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25616625 | 0.91 | MAP2K1 (0.47) | MAP2K1RAF1PDE4BSRCSTK4 | |
| SCHEMBL24028679 | 0.87 | EGFR (0.55) | MAP2K1RAF1SRCEGFRERBB2 | |
| SCHEMBL24028614 | 0.84 | MAP2K1 (0.58) | MAP2K1RAF1PDE4BSRCSTK4 | |
| SCHEMBL24028680 | 0.80 | GAK (0.50) | EGFR | |
| SCHEMBL24028678 | 0.80 | EGFR (0.55) | RAF1EGFRERBB2 | |
| SCHEMBL25616628 | 0.79 | EGFR (0.45) | MAP2K1PDE4BSRCEGFRERBB2 | |
| SCHEMBL24028327 | 0.74 | KDR (0.47) | — | |
| SCHEMBL6381524 | 0.73 | MAP2K1 (0.67) | MAP2K1RAF1SRCEGFRERBB2 | |
| SCHEMBL31084986 | 0.72 | SRC (0.74) | MAP2K1RAF1SRCEGFRERBB2 | |
| SCHEMBL24028333 | 0.72 | MET (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023086638-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2021231726-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | MAP2K1 3751/4885RAF1 1676/4885PDE4B 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.